Integrated Biopharma Stock Current Liabilities
| INBPDelisted Stock | USD 0.33 0.00 0.00% |
Integrated Biopharma fundamentals help investors to digest information that contributes to Integrated Biopharma's financial success or failures. It also enables traders to predict the movement of Integrated OTC Stock. The fundamental analysis module provides a way to measure Integrated Biopharma's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Integrated Biopharma otc stock.
Integrated |
Integrated Biopharma OTC Stock Current Liabilities Analysis
Integrated Biopharma's Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Current Integrated Biopharma Current Liabilities | 11.79 M |
Most of Integrated Biopharma's fundamental indicators, such as Current Liabilities, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Integrated Biopharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
CompetitionIn accordance with the recently published financial statements, Integrated Biopharma has a Current Liabilities of 11.79 M. This is 99.77% lower than that of the Personal Products sector and 98.8% lower than that of the Consumer Staples industry. The current liabilities for all United States stocks is 99.85% higher than that of the company.
Integrated Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Integrated Biopharma's direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of Integrated Biopharma could also be used in its relative valuation, which is a method of valuing Integrated Biopharma by comparing valuation metrics of similar companies.Integrated Biopharma is currently under evaluation in current liabilities category among its peers.
Integrated Fundamentals
| Return On Equity | 0.13 | ||||
| Return On Asset | 0.0336 | ||||
| Profit Margin | 0.04 % | ||||
| Operating Margin | 0.03 % | ||||
| Current Valuation | 12.05 M | ||||
| Shares Outstanding | 29.95 M | ||||
| Shares Owned By Insiders | 68.58 % | ||||
| Shares Owned By Institutions | 0.06 % | ||||
| Price To Earning | 2.52 X | ||||
| Price To Book | 0.56 X | ||||
| Price To Sales | 0.21 X | ||||
| Revenue | 56.25 M | ||||
| Gross Profit | 6.55 M | ||||
| EBITDA | 3.54 M | ||||
| Net Income | 3.84 M | ||||
| Cash And Equivalents | 343 K | ||||
| Cash Per Share | 0.01 X | ||||
| Total Debt | 53 K | ||||
| Debt To Equity | 0.11 % | ||||
| Current Ratio | 3.16 X | ||||
| Book Value Per Share | 0.62 X | ||||
| Cash Flow From Operations | 4.09 M | ||||
| Earnings Per Share | 0.11 X | ||||
| Number Of Employees | 147 | ||||
| Beta | 0.52 | ||||
| Market Capitalization | 11.2 M | ||||
| Total Asset | 25.25 M | ||||
| Retained Earnings | (59.89 M) | ||||
| Working Capital | 913 K | ||||
| Current Asset | 12.7 M | ||||
| Current Liabilities | 11.79 M | ||||
| Net Asset | 25.25 M |
About Integrated Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Integrated Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Integrated Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Integrated Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this otc stock, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Integrated Biopharma
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Integrated Biopharma position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Integrated Biopharma will appreciate offsetting losses from the drop in the long position's value.Moving against Integrated OTC Stock
| 0.51 | LSF | Laird Superfood | PairCorr |
| 0.47 | LW | Lamb Weston Holdings Sell-off Trend | PairCorr |
| 0.41 | BRCNF | Burcon NutraScience Corp | PairCorr |
| 0.34 | K | Kellanova | PairCorr |
| 0.34 | FRPT | Freshpet | PairCorr |
The ability to find closely correlated positions to Integrated Biopharma could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Integrated Biopharma when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Integrated Biopharma - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Integrated Biopharma to buy it.
The correlation of Integrated Biopharma is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Integrated Biopharma moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Integrated Biopharma moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Integrated Biopharma can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics. Note that the Integrated Biopharma information on this page should be used as a complementary analysis to other Integrated Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Premium Stories module to follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope.
Other Consideration for investing in Integrated OTC Stock
If you are still planning to invest in Integrated Biopharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Integrated Biopharma's history and understand the potential risks before investing.
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Idea Breakdown Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges |